Search Results

Johnson & Johnson exceeded fourth-quarter earnings estimates, reporting nearly $21.4 billion in revenue, as its pharma business faces a patent cliff with Stelara competition entering the market.

JW Therapeutics announced the initiation of clinical study of JWATM214 in patients with advanced hepatocellular carcinoma and the first patient infusion.

Lexaria Bioscience Corp. is pleased to announce additional findings from last year’s human clinical study HYPER-H21-4 (“the Study”) demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions.

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in Massachusetts. Moderna and Vertex received the largest awards and will add over 600 combined jobs.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 (“the Study”) demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure (“BP”).

According to Nova one advisor, the global Collagen market size is expected to hit around USD 21.4 billion by 2030 from valued at USD 10.5 billion in 2021 and growing at a CAGR of 9.2% from 2022 to 2030.

The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

According to Nova one advisor, the global Monkeypox Vaccine And Treatment market size is expected to hit around USD 214.79 million by 2030 from valued at USD 85.43 million in 2022 and growing at a CAGR of 10.26% from 2022 to 2030.